{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:11:29Z","timestamp":1760188289090,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1016\/j.ajem.2003.09.001","type":"journal-article","created":{"date-parts":[[2004,1,15]],"date-time":"2004-01-15T05:21:22Z","timestamp":1074144082000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction"],"prefix":"10.1016","volume":"22","author":[{"given":"Marc","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidar","family":"Arjomand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Charles V","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2003.09.001_BIB1","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0735-1097(99)00351-4","volume":"34","author":"Ryan","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2003.09.001_BIB2","first-page":"397","article-title":"Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction","volume":"1","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2003.09.001_BIB3","first-page":"349","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction","volume":"2","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2003.09.001_BIB4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0140-6736(99)07403-6","article-title":"Assessment of the Safety and Efficacy of a New Thrombolytic Investigators: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2003.09.001_BIB5","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","article-title":"Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb\/IIIa inhibition","volume":"357","author":"Topol","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2003.09.001_BIB6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/hc3101.093866","article-title":"Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin","volume":"104","author":"Ross","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2003.09.001_BIB8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJM199311253292204","article-title":"The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199710163371603","article-title":"A comparison of reteplase with alteplase for acute myocardial infarction","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199700543-00004","article-title":"Evaluation of thrombolytic agents","volume":"54","author":"Bell","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ajem.2003.09.001_BIB12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jama.286.4.442","article-title":"Bolus fibrinolytic therapy in acute myocardial infarction","volume":"286","author":"Llevadot","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ajem.2003.09.001_BIB13","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1074\/jbc.275.14.10112","article-title":"Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator","volume":"275","author":"Stewart","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajem.2003.09.001_BIB14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0196-0644(00)70139-9","article-title":"Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction","volume":"35","author":"Walls","year":"2000","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0149-2918(01)80086-2","article-title":"Tenecteplase","volume":"23","author":"Davydov","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajem.2003.09.001_BIB16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.95.2.351","article-title":"TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial","volume":"95","author":"Cannon","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB17","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/01.CIR.98.25.2805","article-title":"TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators","volume":"98","author":"Cannon","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.77.1.142","article-title":"Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction","volume":"77","author":"Fitzgerald","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.CIR.97.2.211","article-title":"Toward a new frontier in myocardial reperfusion therapy","volume":"97","author":"Topol","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes","volume":"335","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB22","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0140-6736(01)06887-8","article-title":"Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction","volume":"358","author":"White","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2003.09.001_BIB23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2165\/00003495-199040040-00003","article-title":"Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins","volume":"40","author":"Verstraete","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.ajem.2003.09.001_BIB24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0735-1097(97)00258-1","article-title":"Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus and arterial embolism after acute anterior myocardial infarction","volume":"30","author":"Kontny","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2003.09.001_BIB25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0735-1097(98)00612-3","article-title":"Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction\u2014a pilot study","volume":"33","author":"Frostfeldt","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajem.2003.09.001_BIB26","doi-asserted-by":"crossref","first-page":"I12","DOI":"10.1002\/clc.4960241305","article-title":"The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction","volume":"24","author":"Wallentin","year":"2001","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ajem.2003.09.001_BIB27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB29","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB30","first-page":"113","article-title":"Low molecular weight heparins in the management of unstable angina\/non-Q-wave myocardial infarction","volume":"25","author":"Cohen","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ajem.2003.09.001_BIB31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0002-9149(00)01014-6","article-title":"Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction","volume":"86","author":"Cohen","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajem.2003.09.001_BIB32","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0002-9149(96)00152-X","article-title":"Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction","volume":"77","author":"Glick","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ajem.2003.09.001_BIB33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/euhj.2001.3083","article-title":"Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study","volume":"23","author":"Simoons","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajem.2003.09.001_BIB34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.eurheartj.a014691","article-title":"Acute myocardial infarction","volume":"17","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajem.2003.09.001_BIB35","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/01.CIR.0000013402.34759.46","article-title":"Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction","volume":"105","author":"Antman","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB36","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/euhj.2001.2777","article-title":"A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study","volume":"22","author":"Coussement","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajem.2003.09.001_BIB37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2165\/00003495-199856040-00014","article-title":"Abciximab. An updated review of its use in ischaemic heart disease","volume":"56","author":"Foster","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ajem.2003.09.001_BIB38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003495-199856060-00017","article-title":"Tirofiban","volume":"56","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ajem.2003.09.001_BIB39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00003495-199957030-00015","article-title":"Eptifibatide","volume":"57","author":"Goa","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ajem.2003.09.001_BIB40","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.95.4.846","article-title":"Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb\/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators","volume":"95","author":"Ohman","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB41","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1161\/01.CIR.99.21.2720","article-title":"Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators","volume":"99","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB42","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/01.CIR.101.24.2788","article-title":"Trial of abciximab with and without low-dose reteplase for acute myocardial infarction","volume":"101","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB43","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1553-2712.2000.tb00477.x","article-title":"Reducing medication errors","volume":"7","author":"Richards","year":"2000","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.0000081659.72985.A8","article-title":"Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting","volume":"108","author":"Wallentin","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ajem.2003.09.001_BIB45","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1001\/jama.287.15.1943","article-title":"Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery","volume":"287","author":"Aversano","year":"2002","journal-title":"JAMA"},{"year":"2002","author":"Anderson","key":"10.1016\/j.ajem.2003.09.001_BIB46"},{"key":"10.1016\/j.ajem.2003.09.001_BIB47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","article-title":"Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction","volume":"361","author":"Keeley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ajem.2003.09.001_BIB48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1067\/mhj.2003.40","article-title":"Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction","volume":"145","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajem.2003.09.001_BIB49","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB50","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2003.09.001_BIB51","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/S0735-1097(99)00444-1","article-title":"A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial","volume":"34","author":"Ross","year":"1999","journal-title":"J Am Coll Cardiol"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675703002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675703002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T14:57:10Z","timestamp":1760021830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675703002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0735675703002122"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2003.09.001","relation":{},"ISSN":["0735-6757"],"issn-type":[{"type":"print","value":"0735-6757"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2003.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}